CD4 辅助性 T 细胞的表观遗传重编程作为改善癌症免疫治疗的策略。

Epigenetic Reprogramming of CD4 Helper T Cells as a Strategy to Improve Anticancer Immunotherapy.

机构信息

University of Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France.

Centre Hospitalier Universitaire de Besançon, Centre d'Investigation Clinique, INSERM CIC 1431, Besançon, France.

出版信息

Front Immunol. 2021 Jun 28;12:669992. doi: 10.3389/fimmu.2021.669992. eCollection 2021.

DOI:10.3389/fimmu.2021.669992

PMID:34262562

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8273698/

Abstract

Evidences highlight the role of various CD4 helper T cells (CD4 Th) subpopulations in orchestrating the immune responses against cancers. Epigenetics takes an important part in the regulation of CD4 Th polarization and plasticity. In this review, we described the epigenetic factors that govern CD4 T cells differentiation and recruitment in the tumor microenvironment and their subsequent involvement in the antitumor immunity. Finally, we discussed how to manipulate tumor reactive CD4 Th responses by epigenetic drugs to improve anticancer immunotherapy.

摘要

研究证据强调了各种辅助性 T 细胞（CD4 Th）亚群在协调抗肿瘤免疫反应中的作用。表观遗传学在 CD4 Th 极化和可塑性的调控中起着重要作用。在这篇综述中，我们描述了控制 CD4 T 细胞在肿瘤微环境中分化和募集的表观遗传因子，以及它们随后在抗肿瘤免疫中的参与情况。最后，我们讨论了如何通过表观遗传药物来操纵肿瘤反应性 CD4 Th 反应，以改善抗癌免疫治疗。